ArticleImmunity & ageing : I & A2026
Impact of Klotho genotype on lactylation in Alzheimer's disease and mechanistic insights.
Article in Immunity & ageing : I & A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Protein lactylation has emerged as a crucial regulator in the pathogenesis of Alzheimer’s disease (AD). Although the Klotho gene (KL) has been clinically linked to AD, its role in lactylation remains unclear. Here, we investigated the influence of Klotho genotype on lactylation and related inflammatory responses. Wild-type KL and the KL F352V variant were transfected into microglia and BV-2 cells of an AD model to assess effects on protein lactylation and cytokine release, followed by transcriptome sequencing to identify downstream mediators. Functional validation using qPCR, ELISA, Western blotting, and immunohistochemistry confirmed that KL expression markedly reduced lactylated protein levels and pro-inflammatory factors, while ameliorating pathological features in AD model mice. Transcriptomic analysis highlighted oncostatin M (OSM) as a key gene suppressed by KL, and OSM knockdown decreased both protein lactylation and inflammation, improving AD pathology in vivo. These findings demonstrate that KL protects against AD progression by inhibiting OSM-mediated signaling, thereby attenuating lactylation and neuroinflammation, and provide novel mechanistic insight into the genetic regulation of lactylation in neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.